Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

M. E. Bjørn, K. de Stricker, L. Kjær, K. Ellemann, H. C. Hasselbalch

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstrakt

We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy.

OriginalsprogEngelsk
Sider (fra-til)73-75
Antal sider3
TidsskriftLeukemia Research Reports
Vol/bind3
Udgave nummer2
DOI
StatusUdgivet - 1 aug. 2014

Fingeraftryk Udforsk hvilke forskningsemner 'Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera' indeholder.

Citationsformater